See MNTA ReadMeFirst for additional info on Lovenox.
General information #msg-51227061How large is the anticoagulant market? #msg-26451612 VTE is a big, big problem (Lancet 2008) #msg-53285442 Clinical overview of the new oral anticoagulants (Blood) #msg-53493902 Drug-design overview of the new oral anticoagulants (C&EN) #msg-26701803 Technical overview of traditional anticoagulants
Xarelto (rivaroxaban) #msg-64830766 FDA approval in VTE prevention following hip/knee surgery #msg-30972846 EU approval in VTE prevention following hip/knee surgery #msg-44245112 Questionable data in secondary VTE prevention #msg-61803303 Probable failure in VTE prevention for immobilized patients #msg-58447066 EU filing in acute VTE treatment (but where is FDA filing?) #msg-53887547 Xarelto matches Lovenox/warfarin in acute DVT
#msg-58447066 FDA submission in AF/stroke prevention (1/5/11) #msg-58426102 EU submission in AF/stroke prevention (1/5/11) #msg-56712414 Xarelto non-inferior to warfarin in ROCKET-AF study #msg-56717469 Musings on Xarelto’s superiority claim in AF (or lack thereof) #msg-63567346 Subgroup data from ROCKET-AF in secondary prevention
#msg-56742484 Musings on the relative merits of Xarelto/Eliquis/Pradaxa (1) #msg-56769950 Musings on the relative merits of Xarelto/Eliquis/Pradaxa (2) #msg-64862315 How will Xarelto/Eliquis/Pradaxa affect US Lovenox sales?
Eliquis (apixaban) #msg-61114160 Approval in EU for VTE prevention… #msg-58061618 …but FDA evidently has concerns (ADVANCE-1 and -2) #msg-58092961 ADVANCE-3 study succeeds in VTE prevention #msg-29928836 Phase-3 trials for acute VTE treatment
#msg-64534413 BMY/PFE’s big win in AF (Matt Herper blog) #msg-64521497 Phase-3 ARISTOTLE study in AF hits all endpoints #msg-54576974 Eliquis superior to aspirin in phase-3 AVERROES study
#msg-56742484 Musings on the relative merits of Xarelto/Eliquis/Pradaxa (1) #msg-56769950 Musings on the relative merits of Xarelto/Eliquis/Pradaxa (2) #msg-64862315 How will Xarelto/Eliquis/Pradaxa affect US Lovenox sales? #msg-19134406 BMY, PFE ink worldwide Eliquis partnership
Pradaxa (dabigatran) #msg-27956748 EU approves Pradaxa for VTE prevention (but what about FDA?) #msg-51315844 Non-inferior to Lovenox in VTE prevention (RE-NOVATE 2) #msg-21155926 Non-inferior to Lovenox in VTE prevention (RE-NOVATE) #msg-44244839 Data from first phase-3 trial in acute VTE
#msg-25152872 ACS program presumably dead (no update since 2007)
#msg-55725156 FDA approves Pradaxa in AF/stroke prevention #msg-62113814 CHMP approves Pradaxa in AF/stroke prevention
#msg-56742484 Musings on the relative merits of Xarelto/Eliquis/Pradaxa (1) #msg-56769950 Musings on the relative merits of Xarelto/Eliquis/Pradaxa (2) #msg-64862315 How will Xarelto/Eliquis/Pradaxa affect US Lovenox sales?
Lixiana (edoxaban) #msg-48661173 Musings on approval in Japan for VTE prevention #msg-46218043 Global phase-3 in VTE prevention #msg-57277975 Global phase-3 in AF/stroke prevention #msg-34100787 Comparable safety to warfarin in AF (phase-2)
Darexaban (YM150) #msg-55022218 Astellas seeks approval for VTE prevention in Japan #msg-55025487 Overview of Darexaban programs in various indications
Betrixaban #msg-61300408 Too little, too late: MRK returns rights to Portola #msg-47847796 Phase-2 safety data vs warfarin in AF #msg-21106352 Phase-2 data vs Lovenox in VTE prevention
Arixtra #msg-65132332 FDA approves generic Arixtra #msg-54742945 Arixtra is wasteful in treatment of SVT #msg-10569101 Arixtra bests Lovenox in ACS (2006 study)
Miscellaneous (in alphabetical order) #msg-41143344 Ablynx starts phase-2 of ALX-0081 in PCI #msg-40720487 Ablynx phase-1 ALX-0681 results in healthy volunteers #msg-39348082 ARYX’s Tecarfarin whiffs in phase-3 #msg-36811828 AZN reports phase-2 data for AZD0837 #msg-64489315 Endotis starts phase-2a trial for reversible anticoagulant #msg-30965016 LLY terminates FXa program #msg-30353872 MYRX MPC-0920 begins phase-1 #msg-31461171 NUVO reports phase-1b data for NU172 #msg-57275734 Octapharma pursues warfarin-reversal program #msg-46648382 Otamixaban ho-hum in phase-2 ACS study #msg-27187973 Paion’s Solulin completes phase-1 #msg-28742653 Paion acquires flovagatran rights #msg-56742275 Portola targets LMWH reversal #msg-59697467 PYMX phase-2 for heparin reversal in PCI #msg-50887012 PYMX phase-1b data for Lovenox reversal #msg-53193787 PYMX phase-1b/2a data for heparin reversal #msg-55348772 Regado’s phase-2a data for RB006/RB007 #msg-55640856 Musings on Regado’s threat to MNTA’s M118 #msg-63888132 SNY reports phase-3 data for Semuloparin (f/k/a AVE5026) #msg-46648462 SNY’s Otamixaban is not quite dead (yet) #msg-53375883 Takeda’s TAK-442 in ACS and VTE prevention #msg-62473925 TB-402 (FVIII inh) enters phase-2b #msg-60525364 Warfarin pharmacogenetics study sponsored by CMS